Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Common Equity (2016 - 2025)

Historic Common Equity for Iradimed (IRMD) over the last 13 years, with Q3 2025 value amounting to $98.4 million.

  • Iradimed's Common Equity rose 1788.19% to $98.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $98.4 million, marking a year-over-year increase of 1788.19%. This contributed to the annual value of $86.8 million for FY2024, which is 2156.06% up from last year.
  • As of Q3 2025, Iradimed's Common Equity stood at $98.4 million, which was up 1788.19% from $94.3 million recorded in Q2 2025.
  • Iradimed's Common Equity's 5-year high stood at $98.4 million during Q3 2025, with a 5-year trough of $62.5 million in Q1 2022.
  • Moreover, its 5-year median value for Common Equity was $72.2 million (2021), whereas its average is $75.2 million.
  • As far as peak fluctuations go, Iradimed's Common Equity plummeted by 305.79% in 2023, and later surged by 2156.06% in 2024.
  • Quarter analysis of 5 years shows Iradimed's Common Equity stood at $72.2 million in 2021, then grew by 2.08% to $73.7 million in 2022, then dropped by 3.06% to $71.4 million in 2023, then rose by 21.56% to $86.8 million in 2024, then increased by 13.28% to $98.4 million in 2025.
  • Its last three reported values are $98.4 million in Q3 2025, $94.3 million for Q2 2025, and $90.1 million during Q1 2025.